

The Important Connection between Down Syndrome and Alzheimer's Disease - What you need to know Dean M. Hartley, Ph.D. Director of Scientific Initiatives Alzheimer's Association

RAND Report - NEJM:

Dementia Costliest Disease in the US

Bloomberg.com | Businessweek.com | Bloomberg TV C | Premium *

BloombergBusinessweek Global Economics



Alzheimer's: The Costliest Killer

Dementia tops cancer, heart disease in cost


Dementia is based on clinical symptoms




- Dementia manifest as problems with thinking and social abilities that interfere with daily functioning
- Alzheimer's is the most common form
- Many mixed cases
- Some dementia mimic Alzheimer's but are reversible

Alzheimer's is Underfunded

<u>% Change in Deaths</u> (2000-2013)



Research Funding FY14 (in Billions)



Our vision is a world without Alzheimer's disease



Our goals:

- Provide care and support
- Increase Concern & Awareness
- Public Policy & Advocacy Efforts
- Advance research

The Alzheimer's Association championed 2 major legislations in the fight against Alzheimer's

- National Alzheimer's Project Act (NAPA)

 National Plan
- 2. Alzheimer's Accountability Act (AAA) - Professional Judgment Budget
- National Plan to Address Alzheimer's Disease

alzheimer's $\ref{eq:station}^{\circ}$

THE WALL STREET JOURNAL.

Home World U.S. Politics Economy Business Tech Markets Opinion Arts Life Real Estate

FOLITICS Hillary Clinton Calls for \$2 Billion in Alzheimer's Research, Cure by 2025

Democratic presidential front-runner seeks dramatic rise in government research spending



Hillary Clinton unveiled her plan:

Spend \$2 billion a year

Next 10 years

Global Leader in Alzheimer's Research

- Currently funding \$78 million 350 active projects in 21 countries
- Fund across critical research needs and gaps
- Global Impact
 - Number 1 among worldwide profits
 - Ranked as 3rd highest impactful funder by publications**



Collaborative Research Initiatives Down Syndrome & Alzheimer's disease


ALZHEIMER'S ASSOCIATION, LINDA CRNIC INSTITUTE FOR DOWN SYNDROME, AND GLOBAL DOWN SYNDROME FOUNDATION LAUNCH NEW RESEARCH GRANTS PROGRAMS

\$2.2 million has been provided to fund research to understand the development of Alzheimer's in individuals with Down syndrome and the general population and possible treatments

alzheimer's R association









What is Alzheimer's Disease?





Alzheimer's Disease



Down's Patients Are at a Much Greater Risk to Develop AD








alzheimer's $igtrianglessim bassociation^\circ$


What is happening in the brain?



ventricles enlarge

cortex shrivels, especially near hippocampus

AD brain = smaller overall



What about treatments?



Pharmaceutical Alzheimer's Therapies and Diagnostics

Therapeutic

Cholinesterase Inhibitors

tacrine (Cognex; no longer marketed in US) donepezil (Aricept) rivastigmine (Exelon) galantamine (Razadyne)


Glutamate Moderators memantine (Namenda)

Combination

donepizil/memantine (Namzaric; approved Dec. 2014)

Diagnostic

Amyloid PET Imaging florbetaben (Neuraceq) florbetapir (Amyvid) flutemetamol (Vizamyl)



Experimental Drug Trial Results: Potential Disease Modifying Treatments

- Solanezumab (Lilly)
 - New analysis of results from two prior phase 3 studies suggests it may slow cognitive decline
 - On-going Phase 3 used Amyloid PET to enroll participants

Aducanumab (Biogen)


- Small Phase 1b suggests may slow cognitive decline in people w/ mild Alzheimer's
- Launched two Phase 3 clinical trials using Amyloid PET to enroll participants







alzheimer's $\ref{eq:station}^{\circ}$




Early Detection & Diagnosis: Biomarkers and Modernizing Diagnosis of Alzheimer's



Modernizing the Diagnosis of Alzheimer's


Normal

Alzheimer's disease



Amyloid vs. Tau PET imaging

70 y/o MMSE =27




PiB

T807

Courtesy of Keith Johnson, MD First study AAIC 2013

Possible Prevention of Alzheimer's?

Abnormal



Possible Prevention of Alzheimer's

- <u>A4/LEARN</u> Anti Amyloid Asymptomatic Alzheimer's disea trial
- <u>API</u>: Alzheimer's Prevention Initiative Trials
- **TOMMORROW** Clinical Trial



 <u>DIAN – TU</u>: Dominantly Inherited Alzheimer's Network – Trials Unit

alzheimer's ℜ association® trialmatch

A first-of-its-kind, free, confidential, online and phone-based tool that provides comprehensive clinical trial information and an individualized trial matching service for people with Alzheimer's and related dementias. Colorado Chapter Linda Mitchell President & CEO <u>24-hour</u> <u>Helpline:</u> <u>1.800.272.3900</u>

Offices: Colorado Springs Office: 719-266-8773 **Denver Office:** 303-813-1669 **Durango Office:** 970-259-0122 Fort Collins Office: 970-472-9798 **Greeley/Evans Office:** 970-392-9202 **Grand Junction Office:** 970-256-1274 **Pueblo Office:** 719-544-5720

Broncos Announce Flagship Partnership With Alzheimer's Association Colorado Chapter



Thank you You can make a difference!

www.alz.org









Rocky Mountain Alzheimer's Disease Center SCHOOL OF MEDICINE | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

Alzheimer's and Down Syndrome


Working together to solve a \$trillion problem

Huntington Potter, Ph.D.

Professor and Director Alzheimer's Disease Programs Department of Neurology and Linda Crnic Institute for Down Syndrome CU Denver/AMC



The Down Syndrome and Alzheimer's Disease Connection



Alzheimer's Disease

- >5 million patients
- ~\$172 billion annual cost

- 10% of people over age 65
- 40-50% of people over age 85

Down Syndrome

- ~400,000 patients
- ~\$19 billion annual cost

- 1/691 live births
- 100 % acquire features of AD







Problem: Need to Forge Links between AD and DS Efforts

Solution: COLLABORATION in

Research, Education and Advocacy







Rocky Mountain Alzheimer's Disease Center school of medicine | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

A Network of Affiliates

The Global Down Syndrome Foundation is part of a network of affiliate organizations that work closely together on a daily basis to deliver on our mission, vision, values, and goals:



Global: was established as a 501(c)3 in 2009 and is "Dedicated to significantly improving the lives of people with Down syndrome through Research, Medical Care, Education, and Advocacy"

✤<u>Affiliates are:</u>

- Established with a lead gift from Anna & John J. Sie Foundation
- Must work closely together to benefit people with Down syndrome
- Must be self-sustaining financially







Collaboration between Global Down Syndrome Foundation and Alzheimer's Association

- 1. 2012 DS-AD Workshop in Chicago
- Joint Grant Program for Research on AD in DS \$2.2 million 2013-2015
- 3. 2015 DS-AD Workshop in Chicago
 - Cognition Imaging Biobanking Pathology IRB/Consent







Collaboration between Global Down Syndrome Foundation and NIH

1. 2010 Meeting/Workshop with **NICHD** on DS NIH establishes **DS-Connect**







Rocky Mountain Alzheimer's Disease Center SCHOOL OF MEDICINE | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS


- First NIH 'Request for Applications' on AD and DS: 'Biomarkers of Alzheimer's Disease in Down syndrome' \$5 million/year for 5 years Multiple applications from AD/DS experts world-wide
- Advocacy and Education
 Multiple meetings with legislators
 \$500,000 per year from state of Colorado
 Media education

Washington Post May 22, 2015: "Why Studying Alzheimer's in People with Down Syndrome Could Help Everyone"









John Langdon Down, 1866



Alois Alzheimer, 1907








Rocky Mountain Alzheimer's Disease Center school of medicine | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

BRAIN PATHOLOGY IN ALZHEIMER'S DISEASE

Normal Brain

Alzheimer's Brain



George Glenner and Caine Wong 1984

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA

 $\textbf{A} \boldsymbol{\beta} \, \textbf{Peptide}$









Rocky Mountain Alzheimer's Disease Center SCHOOL OF MEDICINE | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

The Amyloid Precursor Protein Gene Is Encoded on Chromosome 21





The 'Swedish" Alzheimer's Disease Family Inherits a Mutant APP Gene








Rocky Mountain Alzheimer's Disease Center school of medicine | University of Colorado Anschutz Medical Campus

Mice With Mutant APP Gene Accumulate Amyloid Deposits









Rocky Mountain Alzheimer's Disease Center school of medicine | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

RADIAL ARM WATER MAZE START









Rocky Mountain Alzheimer's Disease Center school of medicine | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

RADIAL ARM WATER MAZE FINISH LINE









A RECRIPROCAL AD—DS CONNECTION

Am. J. Hum. Genet. 48:1192-1200, 1991

Review and Hypothesis: Alzheimer Disease and Down Syndrome—Chromosome 21 Nondisjunction May Underlie Both Disorders

Huntington Potter

Department of Neurobiology, Harvard Medical School, Boston










COUNTING CHROMOSOMES










Trisomy 21 In Alzheimer's Disease



Skin Cells

Nerve Cells







CONCLUSION

Alzheimer's Disease and Down Syndrome Are

TWO SIDES OF THE SAME COIN

And should be studied together









IS ENVIRONMENT IMPORTANT?









Caffeine Consumption of AD Patients Is Half That of Normal Subjects














High Blood Caffeine Levels are Associated With Memory Retention









Why are people with Rheumatoid Arthritis protected against Alzheimer's disease?












GM-CSF Reduces AB Deposition In Vivo










How Rheumatoid Arthritis/GM-CSF May Suppress Alzheimer's Disease




- Reduced Amyloid
- Increased Synapses
- Protected Neurons
- Improved Blood Flow

Macrophages Neutrophils Dendritic Cells GM-CSF

GM-CSF (Leukine[®])

NEXT STEP: TRANSLATION INTO HUMANS









Rocky Mountain Alzheimer's Disease Center school of medicine | University of Colorado Anschutz Medical Campus First Steps:

1. Create an Academic Home for Down Syndrome Research




1. Create Rocky Mountain Alzheimer's Disease Center with a focus on Down Syndrome







ROCKY MOUNTAIN ALZHEIMER'S DISEASE CENTER











UNIVERSITY OF COLORADO HOSPITAL

Anschutz Medical Campus

MEMORY AND DEMENTIA CLINIC

To make an appointment:

- Have your referring physician FAX your medical records, insurance information and demographic information to (720) 848-2106.
- Please allow 2 business days for processing of your paperwork. Then CALL (720) 848-2080 to schedule your appointment.
- Be sure to bring any MRI/CT scans, lab results, and pertinent medical records to your appointment.

We accept all PPO/HMO/POS plans. Please call your insurance carrier to verify benefits and cove rage at University of Colorado Hospital. Medicaid and CICP are accepted in available resident's clinic only for a one-time consultation; wait list may apply.



UNIVERSITY OF COLORADO HOSPITAL Anschutz Outpatient Pavilion 1635 Aurora Court | Aurora, CO 80045 | 720-848-2080



Jonathan H. Woodcock, MD Assistant Professor of Neurology Director, Memory and Dementia Clinic



Christopher M. Filley, MD Professor of Neurology



Huntington Potter, PhD Professor of Neurology Director, Alzheimer's Disease Programs

Getting started:

1) Opened a Memory Disorders Clinic









Getting started:

2) Pilot Clinical Trial of Leukine (human GM-CSF) in Alzheimer's Disease









APPRECIATION

Scientists: Antoneta Granic, PhD Tim Boyd, PhD Julbert Caneus Michelle Norden Jaya Padmanabhan, PhD Jiashin Wu, PhD Sergiy Borysov, PhD Csilla Ari, PhD

Funding:Linda Crnic Institute for Down Syndrome
Global Down Syndrome Foundation
Sie Center for Down Syndrome @ Children's Hospital Colorado
UC Denver COM; Dept. Neurology
National Institute on Aging
National Institute on Neurological Diseases and Stroke
Dana Foundation
Colorado Translational Research Imaging Center
Bruce and Marcy Benson





